Is the door open to further investigation with antiangiogenesis in SCLC?
- PMID: 29850194
- PMCID: PMC5949433
- DOI: 10.21037/jtd.2018.03.87
Is the door open to further investigation with antiangiogenesis in SCLC?
Conflict of interest statement
Conflicts of Interest: The authors have no conflicts of interest to declare.
Comment on
-
Another disappointing result, but how good is it?J Thorac Dis. 2017 Jun;9(6):1426-1428. doi: 10.21037/jtd.2017.05.40. J Thorac Dis. 2017. PMID: 28740648 Free PMC article. No abstract available.
References
-
- Tiseo M, Boni L, Ambrosio F, et al. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. J Clin Oncol 2017;35:1281-7. 10.1200/JCO.2016.69.4844 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources